| abstract |
The invention provides a method for predicting the risk of developing persistent macrophage myofasciitis or the adaptation of a treatment of a human subject capable of developing persistent macrophage myofasciitis comprising determining the presence or the absence of at least one nucleotide polymorphism in a biological sample selected from among rs61746812 of the gene AGT2A, rs2373927 of the gene ATG9B, rs3734114 or rs111249277 of the gene ATG10, rs157397 of the gene ULK2, rs4958847 of the gene IGRM, or rs6087598 gene MAP1LC3A. |